



## **Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0**

Guest Editors:

**Prof. Dr. Jagadeesh Bayry**

1. INSERM, Centre de Recherche  
des Cordeliers, Sorbonne  
Université, F-75006 Paris, France  
2. Indian Institute of Technology  
Palakkad, Kerala 678623, India

**Dr. Srinivasa Reddy Bonam**

Department of Microbiology &  
Immunology, University of Texas  
Medical Branch, Galveston, TX  
77550, USA

Deadline for manuscript  
submissions:  
**closed (31 July 2023)**

### **Message from the Guest Editors**

Dear Colleagues,

The importance of vaccination has gained much attention, again, due to the advent of COVID-19 pandemic. Vaccine adjuvants and/or immunomodulators, either directly or indirectly, have become an indispensable component for many (if not all) vaccines, including RNA, DNA, recombinant proteins, inactivated and attenuated, and viral vector vaccines.

We invite potential researchers to submit a research article or a comprehensive/mini/ opinion review article related to vaccines and vaccine adjuvants/immunomodulators against infectious diseases.

Here you can see our previous Special Issue "Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases"

[https://www.mdpi.com/journal/vaccines/special\\_issues/Adjuvant](https://www.mdpi.com/journal/vaccines/special_issues/Adjuvant)

Dr. Jagadeesh Bayry  
Dr. Srinivasa Reddy Bonam  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)